What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy?

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• AJCC. AJCC Cancer Staging Manual. Springer, NY, USA (2010).
   Google Scholar
• Shitara K, Ikeda J, Kondo C et al. Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. Gastric Cancer doi:10.1007/s10120-011-0083-8 (2011) (Epub ahead of print).
   Google Scholar
• Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev.3, CD004064 (2010).
   PubMed Web of Science ®Google Scholar
• Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer72(1), 37–41 (1993).
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer71(3), 587–591 (1995).
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol.8(2), 163–168 (1997).
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized Phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol.18(14), 2648–2657 (2000).
   PubMed Web of Science ®Google Scholar
• Waters JS, Norman A, Cunningham D et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br. J. Cancer80(1–2), 269–272 (1999).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol.24(31), 4991–4997 (2006).
   PubMed Web of Science ®Google Scholar
• Ajani JA, Moiseyenko VM, Tjulandin S et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a Phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J. Clin. Oncol.25(22), 3210–3216 (2007).
   PubMed Web of Science ®Google Scholar
• Ajani JA, Moiseyenko VM, Tjulandin S et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a Phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J. Clin. Oncol.25(22), 3205–3209 (2007).
   PubMed Web of Science ®Google Scholar
• Kos FT, Uncu D, Ozdemir N et al. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer. Chemotherapy57(3), 230–235 (2011).
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Cummins MM, Sourjina T et al. Randomised, non-comparative Phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br. J. Cancer102(3), 475–481 (2010).
   PubMed Web of Science ®Google Scholar
• Shah MA, Shibata S, Stoller RG et al. Random assignment multicenter Phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). J. Clin. Oncol.28(15s), (2010) (Abstract 4014).
   Google Scholar
• Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med.358(1), 36–46 (2008).
   PubMed Web of Science ®Google Scholar
• Koizumi W, Tanabe S, Saigenji K et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br. J. Cancer89(12), 2207–2212 (2003).
   PubMed Web of Science ®Google Scholar
• Ajani JA, Lee FC, Singh DA et al. Multicenter Phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol.24(4), 663–667 (2006).
   PubMed Web of Science ®Google Scholar
• Ajani JA, Rodriguez W, Bodoky G et al. Multicenter Phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J. Clin. Oncol.28(9), 1547–1553 (2010).
   PubMed Web of Science ®Google Scholar
• Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial. Lancet Oncol.9(3), 215–221 (2008).
   PubMed Web of Science ®Google Scholar
• Boku N, Yamamoto S, Fukuda H et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised Phase 3 study. Lancet Oncol.10(11), 1063–1069 (2009).
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol.20(4), 666–673 (2009).
   PubMed Web of Science ®Google Scholar
• Okines AF, Norman AR, Mccloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann. Oncol.20(9), 1529–1534 (2009).
   PubMed Web of Science ®Google Scholar
• Shitara K, Ito S, Sawaki A et al. Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat. Oncology79(3–4), 211–218 (2010).
   PubMed Web of Science ®Google Scholar
• Shitara K, Muro K, Matsuo K et al. Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointest Cancer Res.3(6), 220–224 (2009).
   PubMedGoogle Scholar
• Al -Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol.26(9), 1435–1442 (2008).
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomised Phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer47(15), 2306–2314 (2011).
   PubMed Web of Science ®Google Scholar
• Park S, Lim D, Park K et al. A multicenter, randomized Phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). J. Clin. Oncol.29 (2011) (Abstract 4004).
   Web of Science ®Google Scholar
• Koizumi W, Akiya T, Sato A et al. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial. Jpn J. Clin. Oncol.39(11), 713–719 (2009).
   PubMed Web of Science ®Google Scholar
• Lim T, Lee J, Lee DJ et al. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother. Pharmacol.68(1), 255–262 (2011).
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Mizota A et al. Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer. Gastric Cancer14(2), 155–160 (2011).
   PubMed Web of Science ®Google Scholar
• Kang Y, Ohtsu E, Van Cutsem E et al. AVAGAST: A randomized, double-blind, placebo-controlled, Phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J. Clin. Oncol.28(18S), LBA4007 (2010).
   Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature392(6674), 402–405 (1998).
   PubMed Web of Science ®Google Scholar
• Gravalos C, Jimeno A. HER 2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol.19(9), 1523–1529 (2008).
   PubMed Web of Science ®Google Scholar
• Yano T, Doi T, Ohtsu A et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncology Reports15(1), 65–71 (2006).
   PubMed Web of Science ®Google Scholar
• Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J. Clin. Oncol.18(11), 2201–2209 (2000).
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmen M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol.16(2), 273–278 (2005).
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Ninomiya I, Ohoyama S et al. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer67(11), 2914–2918 (1991).
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet376(9742), 687–697 (2010).
   PubMed Web of Science ®Google Scholar
• Pinto C, Di Fabio F, Siena S et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann. Oncol.18(3), 510–517 (2007).
   PubMed Web of Science ®Google Scholar
• Lordick F, Lorenzen S, Hegewisch-Becker S et al. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter Phase II study of the AIO upper GI study group. J. Clin. Oncol.25(18S), (2007) (Abstract 4526).
   PubMedGoogle Scholar
• Pinto C, Di Fabio F, Barone C et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br. J. Cancer101(8), 1261–1268 (2009).
   PubMed Web of Science ®Google Scholar
• Kim YH, Sasaki Y, Lee KH et al. Randomized Phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results. J. Clin. Oncol.29(Suppl. 4), (2011) (Abstract 87).
   Google Scholar
• Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer.Nat. Rev. Clin. Oncol.8(8), 492–503 (2011).
   PubMed Web of Science ®Google Scholar
• Satoh T, Bang YJ, Wang J et al. Interim safety analysis from TYTAN: a Phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J. Clin. Oncol.28(15S), (2010) (Abstract 4057).
   PubMedGoogle Scholar
• Doi T, Muro K, Boku N et al. Multicenter Phase II study of everolimus in patients with previously treated metastatic gastric cancer. J. Clin. Oncol.28(11), 1904–1910 (2010).
   PubMed Web of Science ®Google Scholar
• Sun W, Powell M, O’Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J. Clin. Oncol.28(18), 2947–2951 (2010).
   PubMed Web of Science ®Google Scholar
• Moehler MH, Hartmann JT, Lordick F et al. An open-label, multicenter Phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer. J. Clin. Oncol.28 (2010) (Abstract e14503).
   Web of Science ®Google Scholar
• Li J, Qin S, Xu J et al. A randomized, double-blind, multicenter, Phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma. J. Clin. Oncol.29, (2011) (Abstract 4019).
   Google Scholar
• Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J. Clin. Oncol.24(14), 2188–2196 (2006).
   PubMed Web of Science ®Google Scholar
• Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med.363(8), 733–742 (2010).
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Hirata Y, Nakagawa H et al. Apoptosis signal-regulating kinase 1 and cyclin D1 compose a positive feedback loop contributing to tumor growth in gastric cancer. Proc. Natl Acad. Sci. USA108(2), 780–785 (2011).
   PubMed Web of Science ®Google Scholar
• Yasumoto K, Yamada T, Kawashima A et al. The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in cxcr4-expressing gastric cancer. Clin. Cancer. Res.17(11), 3619–3630 (2011).
   PubMed Web of Science ®Google Scholar